Summary. We studied the heterogeneity of cytoplasmic isletcell antibodies for cross-reaction with mouse pancreas in 31 recent-onset Type 1 (insulin-dependent) diabetic patients and 31 first-degree relatives with islet-cell autoantibodies detected on human pancreas. Only six Type i diabetic patients displayed islet-cell antibodies binding to human pancreas but not to mouse pancreas. Among 15 first-degree relatives displaying such antibodies which did not react with mouse pancreas, including one identical twin and one subject with polyglandular autoimmunity, none developed diabetes or even lost acute insulin response to intravenous glucose after 5 years of follow-up. By contrast, 14 of 20 (70 %) of the Type 1 diabetic patients with islet-cell antibodies detected on human pancreas, and five first-degree relatives who progressed to a loss of acute insulin response to glucose and then to either Type 1 diabetes or glucose intolerance, also displayed antibodies reactive with mouse islets. Surprisingly, islet-cell antibodies were detectable on mouse pancreas but not on human pancreas in four Type i diabetic patients and in one relative who progressed to diabetes. In the five relatives who progressed to metabolic abnormalities, islet-cell antibody titres on mouse pancreas, quantified by the fluorescence intensity per islet at each serum dilution, progressively increased concomitantly with the loss of acute insulin response to glucose, whereas islet-cell antibody titres on human pancreas remained stable. The usefulness of such quantification was also validated by the fact that antibody titres on mouse pancreas were decreased after 3 months Co < 0.01) in recent-onset Type i diabetic patients, while titres on human pancreas were not. Our results confirm that the use of mouse pancreas, combined with the conventional assay on human pancreas, reveals the heterogeneity of islet-cell autoantibodies. The presence of cross-species reactive islet-cell autoantibodies in subjects at risk may improve the predictive value, indicating relatives at lower risk whose antibodies are unable to bind to mouse islets. It could also allow the identification of subjects who progress to the disease without ever displaying islet-cell autoantibodies detectable on human pancreas. The increase of antibody titres on mouse pancreas during subject follow-up could be indicative of the worsening of the course during the prediabetic phase. Finally, islet-cell autoantibodies detected on mouse pancreas may be more transient after the onset of diabetes than is the more complex mixture of antibodies detected on human tissue.
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Immune and metabolic abnormalities can be detected before clinical Type 1 (insulin-dependent) diabetes mellitus as markers of ongoing beta-cell destruction [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Cytoplasmic islet-cell autoantibodies (ICA) are the strongest predictive markers in subjects at risk [3, 4] . However, the predictive value of ICA is limited because many ICA positive subjects do not progress to diabetes [11, 12] , whereas others become diabetic even though ICA have not been detected on human pancreas.
Heterogeneity of ICA has recently been established. A subset of ICA that did not cross-react with mouse pancreas may confer a low risk for progression to diabetes [13] . This subset may correspond to ICA which give a granular staining restricted to human beta cells [14] . Another subset of ICA cross-reacted with mouse pancreas and may confer a higher risk [13] . It may correspond to antibodies giving a diffuse cytoplasmic staining in all human islet-cell types [14] . Heterogeneous antigenic specificities were also suggested since only some ICA positive sera from Type i diabetic patients were able to block binding of fluorescein-labelled immunoglobulins from patients with ICA giving a granular fluorescence pattern [15] .
According to cross-reaction with mouse pancreas, we studied the cross-species heterogeneity of ICA in Type 1 diabetic patients and in first-degree relatives with regard to the predictive significance.
End-point ICA titres often appear st able on human pancreas during the follow-up of a given subject before the clinical onset of diabetes, precluding the use of conventionalICA to indicate the possible worsening of the course. We have thus evaluated ICA titres on mouse pancreas by quantifying the mean fluorescence intensity per islet for each serum dilution of sequential samples tested with the same mouse pancreas. This method was applied to the follow-up of some first-degree relatives of Type 1 diabetic patients and validated during the follow-up of recent-onset Type 1 diabetic patients. Comparisons were made with the disappearance rate of ICA on human pancreas.
Subjects and methods

Subjects
All the subjects were included in the "Service de Diab6tologie; CHU Nantes". Thirty-one recent-onset ( < 1 month) Type 1 diabetic patients, in whom diagnosis of diabetes was established according to the World Health Organization criteria were studied (16 female, 15 male, mean age 28 _+ 14 years). Thirty first-degree relatives (16 female, 14 male), previously classified as ICA positive on human pancreas were recruited in Nantes from our prospective evaluation of first-degree relatives of patients with Type i diabetes. Their mean age _+ SEM, when the first sample was drawn, was 20 _+ 4 years. None of these relatives displayed diabetes or impaired glucose tolerance when the initial serum was drawn. Successive intravenous glucose tolerance tests (IVGTT) and oral glucose tolerance tests (OGTI') were performed as described below. Control sera for ICA determination were obtained from blood donors without personal or familial history of diabetes or of other autoimmune diseases.
ICA determination on human pancreas
ICA were determined in a blinded manner by indirect immunofluorescence on sections of a human group 0 p ancre as frozen immediately after removal and kept at -70 ~ until cryostat sections (4-5 gm) were obtained. Antibody titres were determined by serial dilutions to end-point, using a fluoresceinated anti-human IgG serum (Wellcome, Dartford, Kent, UK). Results were expressed in Juvenile Diabetes Foundation (JDF) Units. However, to apply the same unit for comparison with the assay on mouse pancreas, which has not been fully standardized, results obtained on human pancreas were sometimes only expressed by end-point titres. Subjects were classified as ICA positive if they had at least two positive samples ( > 5 JDF Units). One ICA positive internal standard sample and the international reference sera accepted by the international workshops were included [16] . In the fourth international islet-cell antibody workshop, our laboratoryhad 100 % sensitivity and 86 % spedficityin blinded analysis of test serum samples, with a limit of detection of 2.5 JDF Units.
ICA determination and quantification on mouse pancreas
Mouse pancreas were obtained from 10-week-old Balb/c mice (Charles River, St Aubin les Elbeuf, France). They were snap frozen in liquid N2 and stored at -70~ Serial cryostat sections (5 gm) were obtained, and ICA were detected by indirect immunofluorescence. All human sera (1 ml) were absorbed overnight at 4~ with 1 nag of acetone and methanol-extracted mouse liver powder (Sigma, St Louis, Mo., USA). The sections were incubated overnight at room temperature with sera from diabetic, relative, or control subjects at serial dilutions (1:2 to 1:256) in 10 mmol/1 phosphate buffered saline pH 7.2. After washing, the sections were developed with fluoresceinated rabbit (F(ab')2 fragments anti-human IgG 779 (H + L) (Bioatlantic, Nantes, France), for 30 min at room temperature. After washing, the sections were observed with a Leitz fluorescence microscope.
In order to follow-up the fluorescence obtained with sequential samples from each subject, the dilutions of each serum were tested on serial sections of the same batch of two mouse pancreases. They were then tested on sections from another batch of two pancreases on a different day. All sections were read by two independent observers who agreed to 96 % without knowledge of the sample tested. Each section was scored according to three parameters: end-point titre, number of fluorescent islets and mean fluorescence intensity per islet for each serum dilution. At least 50 islets were evaluated for each dilution. The percentage of fluorescent islets was calculated for each serum dilution among the total number of islets within the two serial sections from the two batches of pancreas. The intensity of fluorescence was graded on each islet, from 0 (no staining) to 3 (maximal staining). The scores were expressed as integer values to generate the mean intensity of fluorescence + SEM for each serum dilution, and to allow comparison between sequential samples from a given subject. Furthermore, to take into account both variations of end-point titres and of intensities of fluorescence along the range of dilutions, an index of ICA titre was calculated as the area under the "curve of fluorescence intensity" from the i : 4 dilution to the end-point dilution. All sera were tested in at least two separate assays. In each assay, one positive internal standard (80 JDF Units on human pancreas) and one negative sample serially diluted were included as assay quality controls. The negative control was read as negative on 30 occasions. The positive control was always read as positive, with a mean end-point titre of 1/64 and an inter-assay variation of 0.5 titration steps (estimated from the SD).
Metabolic study
Acute insulin responses to i.v. glucose (AIRG) were evaluated on the morning after a 12-h overnight fast, as previously described [17] . Briefly, catheters were inserted into both antecubital veins and 0.5 g/kg body weight of 30 % glucose was injected over 2 min _+ 5 s. Blood samples were taken 10 min prior to each bolus and at 1 and 3 min after the end of the injection. Each sample was drawn in less than 15 s and kept on ice until centrifugation. Plasma was then frozen at -20~
Immunoreactive insulin (IRI) concentrations were measured by radioimmunoassay (SB-INSI-5; CIS International, Saclay, France) with 125I-porcine insulin, human insulin as a standard, and guinea pig antiserum to human insulin. Separation was carried out with polyethylene glycol. Undiluted plasma leading to immunoreactive insulin values above 60 gU/ml was further diluted until falling in the linear portion of the standard curve. Sensitivity of the assay was 2.5 gU/ml. The intra-and inter-assay coefficients of variation were less than 10%. AIRG was calculated as the sum of 1 + 3 min insulin values (IRI 1 + 3 min). Inter-and intra-individual variations of AIRG were previously reported in adult healthy control subjects [18] . A polynomial regression (p < 10 -5) was previously established between age and AIRG with a peak during puberty [t9]. With this standard chart for AIRG, a "low" AIRG for each pubertal stage was defined as a value of IRI i + 3 rain below the first percentile: 29 gU/ml for adults and 40 btU/ml for Tanner's stage 4-5. OGTI" (75 g glucose load for adult subjects and 1.75 g/kg for children) were performed. Impaired glucose tolerance and diabetes mellitus were defined according to the criteria of the World Health Organization. Blood glucose was measured using a glucose oxidase method.
Statistical analysis
Statistical differences between groups were evaluated using twotailed Student's t-tests for paired or unpaired observations, the nonparametric Mann-Whitney tests, and the Wilcoxon's test. The chisquare test was performed to evaluate the significance of differences between percentages. Least-square linear regression was used for correlation analysis. Differences were considered significant atp less than 0.05. . Surprisingly, four out of 11 patients in whom ICA could not be detected on human pancreas, displayed ICA on mouse pancreas. Thus, the highest positivity in disease is afforded by the detection of ICA either on mouse or on human pancreas (77 % ). With respect to all 31 patients, no correlation was found between ICA titres on human and on mouse pancreas (Fig. 1) . However, when patients who showed a total discordance between the two tests were excluded, i. e. when only those subjects were considered who displayed antibodies on human and mouse pancreases, a correlation was found between titres on both tissues (p < 0.05). ICA detected on mouse pancreas quickly disappeared after the onset of diabetes. Figure 2 illustrates in two patients, that a decrease of ICA titres on mouse pancreas was generally detected by the simultaneous decrease of two parameters; end-point dilution, and mean fluorescence intensity at each serum dilution. However, in some instances, a decrease of fluorescence intensity was revealed without detectable change of end-point titre. The index of ICA titre (area under the curve of fluorescence intensity) decreased significantly for all the subjects (p < 0.01) as early as 3 months after the onset of the disease (Fig. 3 ). This contrasted with the non-significant decrease of ICA titres on human pancreas up to i year, as previously described [20] . This decrease was the most clear after 6 months (p < 0.001) when the percentage of patients without ICA on mouse pancreas was 86%. A R SaY et al.: Cross-reaction of human ICA with mouse islets 
ICA in relatives of Type 1 diabetic patients
Among 30 first-degree relatives of Type 1 diabetic patients who displayed ICA on human pancreas at entry in our prospective study, 16 did not bind at any dilution (undiluted to 1 : 256) to mouse islets. The remaining 14 relatives displayed ICA which cross-reacted with mouse pancreas. With respect to all 30 relatives, no correlation was found between ICA end-point titres on human and on 22 years, DR 3/4 and DR 4/4) progressed to overt diabetes Fig.3 . Quantification of ICA on sequential serum samples from after 6 and 9 months, respectively. Two other relatives diabetic patients, ICA were quantified either into JDF Units on (one female and one male, 20 and 18 years, DR 3/4 and human pancreas (upper panel; log scale), or as the area under the "fluorescence curve" from the 1 : 4 dilution to the end-point dilution DR 4/4) progressed to oral glucose intolerance after 4 and on mouse pancreas (lower panel). For each patient, the sequential 5 years, respectively. results (at entry, and after 3, 6, 9, and 12 months) arelinked by aline.
Furthermore, clear-up variations were detectable Close to each point, the corresponding ICA titre on the pancreas when the sera of these four relatives were quantitated on from the other species is indicated mouse pancreas during the follow-up. Figure 6 shows typical fluorescence intensity curves as a function of dilutions from sequential serum samples in the two relatives mouse pancreas (Fig. 4) . However, when only those relawho progressed to glucose intolerance. A progressive intives who displayed antibodies on human and mouse pancrease of ICA titres can be noted by the displacement of creases were considered, a correlation was found between end-point titres of by the increase of fluorescence intentitres on both tissues (p < 0.01).
sity. It was also reflected by an increased number of fluoThe 16 relatives with ICA binding only to human panrescent islets (data not shown). In sequential samples durcreasatentrydidnotconverttocross-reactivitywithmouse ing the follow-up of these relatives with ICA binding to pancreas during testing of at least four samples corremouse pancreas (Fig.7) , a progressive increase of the sponding to a 5-year follow-up. The AIRG of these subindex (area under the fluorescence intensity curve) conjects, quantified every 6 months, remained above the cuttrasted with the stability of ICA titres on human pancreas. off of the first percentile of control subjects of similar age.
The four subjects who developed metabolic abnormalities None of these 16 relatives progressed to diabetes. They indisplayed rises of 24 to 94 % of this index between the cluded one non-diabetic 35-year-old identical twin (HLA initial and final samples. DR 4/6) of a proband who had developed diabetes at the Moreover, one first-degree relative (20 years, DR 3/4) age of 15 years. This twin displayed stable ICA titres of a diabetic proband, developed diabetes after 3 years of (40 JDF Units) on human pancreas over 5 years. Another follow-up, without ever displaying detectable ICA on (Fig. 5) . When tested on mouse pancreas, no ICA were detected over 2 years (three sequential samples), but they appeared i year before the onset of diabetes and increased in the following sample (6 months before the onset of the disease) (Fig. 7) .
Discussion
According to cross-reaction with mouse pancreas, our study reinforces previous findings concerning ICA heterogeneity [13] . At least two subsets of ICA were found in Type i diabetic patients and in first-degree relatives: ICA which bound to human pancreas but not to mouse pancreas, and ICA which cross-reacted with mouse pancreas. In addition, ICA were detected on mouse pancreas in some Type i diabetic patients without ICA detectable on human pancreas, and in one first-degree relative who progressed to diabetes without ever displaying ICA on human pancreas.
ICA which do not cross-react with mouse islets may be indicative of a low risk of progression to diabetes [13] . They may correspond to ICA giving a granular staining mainly restricted to beta cells and most likely directed against glutamate decarboxylase [14, 21] identified as the 64 kDa antigen [22] . ICA which cross-react with mouse pancreas could confer a higher risk [13] . They may correspond to antibodies which give diffuse cytoplasmic staining in all islet-cell types [1] , and their targets could be glycolipids [23] . In our study, all relatives who progressed to metabolic abnormalities, as well as most Type 1 diabetic patients, displayed ICA which reacted with mouse pancreas. Those ICA may result from a break of immune self-tolerance to several non-species-specific islet molecules. Conversely, fewer diabetic patients displayed ICA which reacted only with human pancreas, and none of the ICA positive relatives with this pattern, including an identical twin [24] and a subject with polyglandular autoimmunity [25] , developed diabetes. Those ICA only detectable on human pancreas may result from a break of self-tolerance only to beta-cell molecules which rarely leads to the disease. The presence of such ICA that do not cross-react with mouse pancreas may even reflect a protective immune response characterized by an increased frequency of protective HLA haplotypes [13, 26] .
The predictive value of ICA detected on human pancreas becomes greater as their titres increase [3, 4] . However, a high positivity threshold only identifies some of the subjects who progress to the disease. A lower threshold is desirable to detect more patients, but this would require combining the ICA assay on human pancreas with other tests in order to enhance predictive value. Determination of ICA binding to mouse pancreas may improve this predictive value, lowering the "practical cut-off" for ICA positivity on human pancreas, and indicating relatives without mouse cross-reactive ICA. It may also indicate some subjects without ICA on human pancreas who nevertheless progress to diabetes. Our data suggest that some individuals who develop diabetes without displaying ICA on human pancreas may be incorrectly classified as ICA negative when only human tissue is used. ICA which only react with mouse pancreas may, in normal human islets, correspond to epitopes either hidden or expressed below the detection limit when titres are very low. Although human sera in our study were absorbed by mouse liver powder, we cannot exclude that this reaction with mouse but not with human pancreas may have been due to the presence of heterophilic antibodies.
Quantification of ICA on mouse pancreas indicated that ICA titres increased progressively, in conjunction with a loss of acute insulin response to glucose, in all firstdegree relatives who developed metabolic abnormalities. This increase contrasted with the stability of ICA titres on human pancreas, and even occurred in a relative who developed diabetes without ever displaying ICA on human pancreas. Sequential quantification of ICA on mouse pancreas may thus be indicative of a worsening of the course during the prodromal phase. The value of quantifying ICA on mouse pancreas was also validated by the follow-up of recent-onset diabetic patients. In these subjects, ICA titres after 3 months were already decreased on mouse pancreas but not on human pancreas. Although earlier detection of decreased ICA titres on mouse pancreas may have been due to more accurate quantification, it is possible that ICA which cross-react with mouse pancreas are more transient and more closely related to the onset of the disease than is the more complex mixture of ICA detected on human pancreas.
